Clinically Relevant Models
Living & diverse bank of clinically relevant models that correlate with clinical outcomes
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses
Champions’ Non-Small Cell Lung Cancer NSCLC PDX Models
Champions Oncology offers 179* clinically relevant Non-Small Cell Lung Cancer -NSCLC PDX models for oncology studies and drug development. These models are derived from late-stage NSCLC patients, many with smoking histories and prior treatment with Standard of Care therapies. They encompass a broad range of targetable mutations, including a unique EGFR triple-mutant model (CTG-3970). A significant number of the models have been extensively characterized, with 166* having Whole Exome Sequencing (WES), 158* RNA-seq, and 155* having both, along with in vivo drug response data. This comprehensive dataset enables robust exploration of biomarkers associated with response and non-response in NSCLC. More details on these models can be accessed via Champions’ Model Select®.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading NSCLC PDX Models cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history.
-
Access to one of the largest bank of NSCLC PDX models with clinically relevant molecular
and pathological characteristics on the market. -
Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.
-
Includes models pretreated with advanced therapies like checkpoint inhibitors and EGFR-targeted treatments.